Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...
In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...
MedPage Today on MSN1d
Nonsteroidal Topical OK'd for Atopic DermatitisThe FDA approved tapinarof cream 1% (Vtama) for eczema in individuals ages 2 years and older, drugmaker Organon announced on ...
The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...
The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Read the entire package insert before using this ...
According to newly published research, the exposure to nature provided by the Re-Connecting Nature forest microbe extract has ...
Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...
GlobalData on MSN2d
FDA approves Galderma’s Nemluvio to treat atopic dermatitisThe US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for ...
This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to ...
Monday announced that the U.S. Food and Drug Administration (FDA) has approved Vtama (tapinarof) cream, an aryl ...
Organon's VTAMA (tapinarof) cream is a first-in-class therapy with new FDA approval for atopic dermatitis in adults and children aged 2 and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback